Streetbeat News

Regulatory

DJT

FXI

SPY

Chinese hackers reportedly targeted phones used by Trump and Vance, potentially accessing data through a breach of American telecommunications systems.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 6:08 pm

BTCUSD

ETHUSD

Federal investigators are probing Tether, a major cryptocurrency firm, for potential violations of anti-money-laundering and sanctions rules. The investigation focuses on whether Tether has been used to fund illegal activities or launder money. Tether may face penalties if found to have done business with groups on the U.S. sanctions list.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 5:57 pm

LLY

REGN

SNY

Eli Lilly's Ebglyss, a newly FDA-approved eczema drug, shows promising results in improving skin and itch in patients previously treated with Sanofi/Regeneron's Dupixent. The Phase 3b ADapt study demonstrated significant improvements in patients with moderate-to-severe atopic dermatitis, with a high percentage achieving EASI-75 and itch relief. Ebglyss has been approved in the US, EU, and Japan.

Portfolio Pulse from Vandana Singh

October 25, 2024 | 5:57 pm

PXDT

Pixie Dust Technologies (PXDT) shares dropped 43% due to the company's decision to voluntarily delist its ADRs from NASDAQ, citing high costs. The delisting will occur on November 15, and the ADR program will end by January 21, 2025. PXDT will also deregister with the SEC by February 12, 2025.

Portfolio Pulse from Henry Khederian

October 25, 2024 | 5:20 pm

PXDT

Pixie Dust Technologies is set to delist its ADR units from the Nasdaq Capital Market and will submit a deregistration application with the SEC, leading to a decline in its share price.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 5:20 pm

JNJ

Johnson & Johnson's drug Tremfya shows significant efficacy in treating moderate plaque psoriasis with low body surface area, achieving high clearance rates in a Phase 3b study. Tremfya also received FDA approval for ulcerative colitis, contributing to its $1.01 billion sales in Q3.

Portfolio Pulse from Vandana Singh

October 25, 2024 | 5:19 pm

HOLX

The FDA has issued a safety communication advising against the use of BioZorb Marker devices by Hologic Inc. due to reports of serious adverse events in patients. Hologic has initiated a voluntary recall of all unused BioZorb Markers. The FDA emphasizes that these devices are not approved for certain uses, such as radiation treatment markers, and advises healthcare providers to monitor patients with these implants.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 5:13 pm

ACHR

DAL

JOBY

The FAA has issued a new rule establishing a 'powered lift' category for eVTOL aircraft, paving the way for air taxis in the U.S. Companies like Joby Aviation and Archer Aviation are set to benefit, with plans to launch commercial services by 2025.

Portfolio Pulse from Erica Kollmann

October 25, 2024 | 5:02 pm

CZR

The DOJ supports a lawsuit accusing Las Vegas hotels, including Caesars Entertainment Inc., of using algorithms to fix prices. The case, dismissed by a district court, is now on appeal and could impact similar future cases.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 4:13 pm

CG

TKAMY

Carlyle Group has withdrawn its bid for Thyssenkrupp's defense unit due to indecision from the German government. This decision may impact Carlyle's investment strategy and Thyssenkrupp's future plans for the unit.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 4:08 pm